696 filings
6-K
CANF
Can-Fite Biopharma Ltd
25 Apr 24
Current report (foreign)
7:03am
6-K
CANF
Can-Fite Biopharma Ltd
15 Apr 24
A pivotal Phase III trial for advanced liver cancer, approved by FDA & EMA and a MASH Phase IIb are enrolling patients
7:03am
EFFECT
CANF
Can-Fite Biopharma Ltd
10 Apr 24
Notice of effectiveness
12:15am
S-8
CANF
Can-Fite Biopharma Ltd
5 Apr 24
Registration of securities for employees
4:15pm
POS AM
CANF
Can-Fite Biopharma Ltd
5 Apr 24
Prospectus update (post-effective amendment)
4:15pm
6-K
0zln1zc2t2493hhuhlf
3 Apr 24
Report of Foreign Private Issuer
7:07am
6-K
rmgeesjfud a2yv
28 Mar 24
Can-Fite Reports 2023 Financial Results and Clinical Update
7:05am
6-K
2h5zmmp
11 Mar 24
Report of Foreign Private Issuer
7:27am
6-K
tlbx16 44bcpkuwf
28 Feb 24
Patent has already been issued in other major markets including the U.S., EU, Japan and China
7:06am
SC 13G
tg3 fpss9
14 Feb 24
Can-Fite BioPharma / ARMISTICE CAPITAL ownership change
3:32pm
6-K
gaf9mcmadbzdjz0 tuu
30 Jan 24
Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication
7:24am
6-K
fv6e0j
29 Jan 24
Piclidenoson is a small molecule safe oral drug suitable for the chronic treatment of patients who suffer from moderate to severe plaque psoriasis
7:05am
EFFECT
et5vhio8
8 Jan 24
Notice of effectiveness
12:15am
CORRESP
enj2va4iy8i6nkbyns
3 Jan 24
Correspondence with SEC
12:00am
F-3/A
2ziir 2lzmc
28 Dec 23
Shelf registration (foreign) (amended)
4:16pm
6-K
rltkfg6lspz4nzf6x90m
20 Dec 23
Robust support for Namodenoson’s potential development as an anti-obesity drug, a projected $100 billion market by 2030
7:09am
6-K
g16peff6m5f3b9b 0f6
18 Dec 23
Can-Fite Received FDA Positive Response to Psoriasis Pediatric Plan
7:07am
F-3
6nylzo8v
12 Dec 23
Shelf registration (foreign)
4:15pm
6-K
amwp1l
4 Dec 23
Report of Foreign Private Issuer
7:05am